Tirzepatide cut BMI by about 18% in adolescents with obesity in a phase 3 trial
In SURMOUNT-ADOLESCENTS, 160 teenagers were randomised to the weekly injection or placebo for 72 weeks. It is a BMI result in a single drug-company-funded trial, not an outcomes study.
| Group | Value (%) |
|---|---|
| Tirzepatide | 79.6 |
| Placebo | 28.5 |
Tirzepatide, the dual-hormone injection already approved to treat obesity in adults, has now been tested in adolescents in a dedicated phase 3 trial. The result, published in JAMA, is large on its own terms: over 72 weeks, the drug was associated with an 18.5% reduction in body mass index, against a 0.5% increase in the placebo group [s1].
What the trial did
SURMOUNT-ADOLESCENTS was a phase 3, randomised, double-blind, 72-week trial run at 31 medical research centres and hospitals in Canada, the Czech Republic, Israel, Italy, Poland and the United States, between 16 October 2023 and 2 June 2026 [s1]. It enrolled adolescents aged 12 years to younger than 18 with obesity, or with overweight plus at least one obesity-related complication [s1]. Participants were randomly assigned in a 2:1 ratio to once-weekly subcutaneous tirzepatide, escalated to a maximum tolerated dose of 5, 10 or 15 mg, or to placebo, for 72 weeks, on top of a healthy-lifestyle intervention in both groups [s1]. The trial is registered as NCT06075667 [s2].
The primary endpoint was the percent change in BMI from baseline to week 72 [s1]. A total of 160 participants were randomised — 109 to tirzepatide and 51 to placebo [s1]. Their mean age was 14.6 years, 99 (61.9%) were female, mean body weight was 109.7 kg, and mean BMI was 38.6 [s1].
What it found
At week 72, tirzepatide was associated with an 18.5% reduction in BMI, compared with a 0.5% increase with placebo — an estimated treatment difference of −19.0 percentage points (95% confidence interval −23.9 to −14.1; P<0.001) [s1]. All 10 of the trial's key secondary outcomes were statistically significant in tirzepatide's favour [s1].
The responder analysis gives a feel for how widely that average applied. A BMI reduction of at least 5% was reached by 79.6% of adolescents on tirzepatide, against 28.5% on placebo — a risk difference of 51.2 percentage points (95% CI 36.3 to 66.1; P<0.001) [s1]. The most common adverse events with tirzepatide were gastrointestinal, and mostly mild to moderate [s1].
How to read it
This is a clear, internally consistent efficacy signal in a group where options have been limited, and it should be read as that. It is also a BMI result, not an outcomes result: the trial measured body size over 72 weeks, not whether treated adolescents go on to have fewer heart attacks, less diabetes or better health decades later [s1]. For a drug that would plausibly be taken for years starting in the teens, those longer-term questions are the ones that ultimately matter, and this trial was not built to answer them.
Several limits are worth stating plainly. The trial was modest in size — 160 participants, with only 51 on placebo [s1]. It ran for 72 weeks, which is long for an adolescent drug trial but short against a lifetime of use, and it does not report what happens to weight after the drug is stopped. It was funded by the drug's manufacturer [s1]. And because tirzepatide was given alongside a lifestyle programme, the trial speaks to the drug added to that support, not to the drug alone [s1].
What to watch
The decisions that follow will turn on questions this trial leaves open: whether the BMI reductions are maintained or rebound after treatment ends, how the safety profile reads over years rather than months in a still-growing population, and how regulators and paediatric guideline groups weigh a strong short-term BMI effect against the absence of long-term outcome data. For now, the honest summary is that in one manufacturer-funded phase 3 trial, weekly tirzepatide lowered adolescents' BMI by about 18% more than placebo over 72 weeks [s1].
This article describes clinical-trial results and is not medical advice. Decisions about obesity treatment in adolescents should be made with a clinician.
Sources
More on
Tirzepatide beat semaglutide head to head for weight loss in SURMOUNT-5
The first randomised head-to-head trial of the two obesity drugs gave 751 adults the maximum tolerated dose of each for 72 weeks. Tirzepatide cut weight by 20.2%, semaglutide by 13.7%.
Mazdutide cut body weight by about 17% in a phase 3 obesity trial in China
GLORY-2 randomised 461 Chinese adults with obesity to a weekly GLP-1/glucagon dual agonist or placebo; weight fell 16.65% versus 1.50% at 60 weeks, alongside high rates of nausea and vomiting.
Lifting weights preserved muscle during tirzepatide weight loss in a trial
In 120 adults losing about 22 kg on tirzepatide, adding thrice-weekly resistance training spared roughly 1 kg of lean mass and turned strength loss into strength gain. Fat loss was unchanged.
GLP-1 therapy in a digital clinic cut women's weight 16 kg, with no comparison group
An observational study of 8,127 UK women on GLP-1 drugs, almost all tirzepatide, reported 16.1 kg average loss at six months and 91.4% retention. There was no control arm.